TransCode Therapeutics Files Proxy Statement for Annual Meeting
Ticker: RNAZ · Form: DEF 14A · Filed: Oct 28, 2024 · CIK: 1829635
Sentiment: neutral
Topics: proxy-statement, annual-meeting, governance
TL;DR
TransCode Proxy filed: vote on directors & auditors for Nov 22 meeting.
AI Summary
TransCode Therapeutics, Inc. filed a definitive proxy statement (DEF 14A) on October 28, 2024, for its annual meeting of stockholders on November 22, 2024. The filing outlines the company's governance, executive compensation, and proposals to be voted on by shareholders. Key items likely include the election of directors and ratification of independent auditors.
Why It Matters
This filing provides shareholders with crucial information regarding company leadership and proposals, enabling informed voting decisions that can impact the company's strategic direction and financial performance.
Risk Assessment
Risk Level: low — This is a routine proxy filing detailing governance and shareholder proposals, not indicating immediate financial distress or significant operational changes.
Key Numbers
- 20241122 — Meeting Date (Date of the annual meeting of stockholders.)
- 20241028 — Filing Date (Date the DEF 14A was filed with the SEC.)
Key Players & Entities
- TransCode Therapeutics, Inc. (company) — Registrant
- October 28, 2024 (date) — Filing Date
- November 22, 2024 (date) — Meeting Date
- 6 Liberty Square, #2382, Boston, MA 02109 (address) — Company Business and Mail Address
FAQ
What is the primary purpose of this DEF 14A filing?
The primary purpose is to provide shareholders with information for the annual meeting on November 22, 2024, including details on director elections, executive compensation, and other corporate governance matters.
Who is the filer of this proxy statement?
The filer is TransCode Therapeutics, Inc., as indicated by the 'Registrant' designation.
When is the annual meeting of stockholders scheduled?
The annual meeting of stockholders is scheduled for November 22, 2024.
What is the company's principal business address?
The company's principal business address is 6 Liberty Square, #2382, Boston, MA 02109.
What is the SIC code for TransCode Therapeutics, Inc.?
The Standard Industrial Classification (SIC) code for TransCode Therapeutics, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 4,874 words · 19 min read · ~16 pages · Grade level 13.4 · Accepted 2024-10-28 16:02:18
Key Financial Figures
- $0.0001 — nding shares of common stock, par value $0.0001 per share (the " Common Stock "), at an
- $0.30 — fering"). The public offering price was $0.30 per Share. The July 2024 Offering close
- $2.4 m — e July 2024 Offering were approximately $2.4 million, after deducting fees to Think an
- $30,000 — a non-accountable expense allowance of $30,000 and reimbursement for certain of its of
- $0.375 — 22, 2029, and have an exercise price of $0.375 per share. The Placement Agent Warrants
- $0.7925 — a 62% discount to the Minimum Price of $0.7925. According to published guidance on d
- $1.00 — intained a minimum closing bid price of $1.00 per share (the "Minimum Bid Price Requi
Filing Documents
- tm2426173-2_def14a.htm (DEF 14A) — 242KB
- lg_transcodetheraptm-4c.jpg (GRAPHIC) — 10KB
- px_24transcodepg01-bw.jpg (GRAPHIC) — 254KB
- px_24transcodepg02-bw.jpg (GRAPHIC) — 222KB
- 0001104659-24-111804.txt ( ) — 854KB
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 22 WHERE YOU CAN FIND ADDITIONAL INFORMATION 23 APPENDIX A A-1 i TABLE OF CONTENTS TRANSCODE THERAPEUTICS, INC. PROXY STATEMENT FOR SPECIAL MEETING OF STOCKHOLDERS To Be Held at 9:30 a.m. Eastern Time on November 22, 2024 This proxy statement and the enclosed form of proxy are furnished in connection with the solicitation of proxies by our Board of Directors (the " Board " or " Board of Directors ") for use at the special meeting of stockholders of TransCode Therapeutics, Inc., a Delaware corporation, and any postponements, adjournments or continuations thereof (the " Special Meeting "). The Special Meeting will be held virtually, via live webcast at www.virtualshareholdermeeting.com/RNAZ2024SM, on November 22, 2024, at 9:30 a.m. Eastern Time. References in this Proxy Statement to "we," "us," "our," the "Company" or "TransCode" refer to TransCode Therapeutics, Inc. In addition, unless the context otherwise requires, references to "stockholders" are to the holders of our common stock, par value $0.0001 per share, (" Common Stock "). This proxy statement contains important information for you to consider when deciding how to vote on the matters for which we are soliciting proxies. Please read it carefully. The Special Meeting can be accessed via the internet at www.virtualshareholdermeeting.com/RNAZ2024SM where you will be able to listen to the meeting live, submit questions, and vote online. The Notice of Special Meeting, this Proxy Statement and the form of proxy are first being mailed on or about October 28, 2024, to all stockholders entitled to vote at the Special Meeting. 1 TABLE OF CONTENTS THE INFORMATION PROVIDED IN THE "QUESTION AND ANSWER" FORMAT BELOW IS FOR YOUR CONVENIENCE ONLY AND IS MERELY A SUMMARY OF THE INFORMATION CONTAINED IN THIS PROXY STATEMENT. YOU SHOULD READ THIS ENTIRE PROXY STATEMENT CAREFULLY. QUESTIONS AND ANSWERS ABOUT THE PROXY